EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
March 23, 2015 4:38 PM EDTEPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.80), $0.19 better than the analyst estimate of ($0.99).
For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.
... More